Greenwich LifeSciences(NASDAQ) GLSI

Greenwich LifeSciences helps people who survived breast cancer. It makes treatments to stop the cancer from returning. These therapies help patients stay healthy after surgery.

Fighting Breast Cancer Recurrence

• GLSI-100: Immunotherapy designed to prevent breast cancer recurrence in patients who completed prior treatments.
• GP2: Peptide that targets a protein found on the surface of many breast cancer cells.
• GM-CSF: Substance used to increase the effectiveness of the GP2 immunotherapy.

Global Trial Expansion

• Launched the Flamingo-01 Phase III clinical trial to evaluate GLSI-100 safety and efficacy.
• Expanded clinical operations into Europe to open up to 150 global sites.
• Raised $9.3 million in net proceeds through stock sales during the first half of 2026.
• Adopted the Financial Instruments – Credit Losses accounting standard on Jan. 1, 2023.

Targeting Specific Cancer Proteins

Greenwich targets the HER2/neu protein, which is present in 75% of breast cancers. The company focuses on a specific patient group that has already undergone surgery but remains at high risk for the disease to return.

Funding and Financial Results

• Market cap reached $343.0 million in Q2 2026, up 182.8% year over year.
• Research and development expenses rose 54% year over year to $8.8 million for the six-month period ended June 30, 2026.
• Net loss was $9.6 million for the six months ended June 30, 2026.
• Cash and cash equivalents totaled $8.9 million as of June 30, 2026.
• The company sold 379,762 shares of common stock between Jan. 1, 2026 and June 30, 2026.

The Path Forward

Greenwich has grown from an early-stage researcher into a firm conducting international Phase III clinical trials. It maintains a lean team of 13 employees while managing a global expansion of its cancer treatment studies.